Press Releases


Prexton announces initiation of phase II clinical testing in Parkinson’s disease
Prexton announces initiatio ...

Study will evaluate first-in class treatment in six European countries Downloa ...

Learn More
Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic
Prexton Therapeutics Series ...

Forbion & Seroba co-led funding, forming international consortium of M ...

Learn More
Maladie de Parkinson : Prexton Therapeutics finalise son essai clinique de phase 1
Maladie de Parkinson : Prex ...

L’étude montre que le modulateur allostérique positif mGluR4 est sûr et bie ...

Learn More
Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial
Parkinson’s disease: Prex ...

First clinical trial with an mGluR4 positive allosteric modulator, a first-in-cl ...

Learn More
Prexton Therapeutics raises 8.7 million euros (10 million dollars) in a Series A round
Prexton Therapeutics raises ...

Swiss based startup attracts venture funding from leading European VC firms ...

Learn More
PREXTON THERAPEUTICS ANNOUNCE
PREXTON THERAPEUTICS ANNOUN ...

January 22, 2013. Prexton Therapeutics will  develop novel mGluR4 PAM seri ...

Learn More
Merck Serono Announce
Merck Serono Announce

July 30, 2012. Merck Serono announces the creation of the first spin-off company ...

Learn More